TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8774269

Group type: EXPERIMENTAL
Intervention: Creatine supplement (5 g of creatine plus 1 g of glucose)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Glucose placebo (6 g of glucose)
Number of subjects: 34
Study: 1377412

Group type: COMPARATOR
Intervention: DDAVP infusion
Number of subjects: 0
Study: 6235582

Group type: EXPERIMENTAL
Intervention: Bacterial extract
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 28734553

Group type: EXPERIMENTAL
Intervention: Higher Dietary Inflammatory Index (DII)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Lower adherence to Mediterranean diet (MeDiet)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Higher DII score
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Pro-inflammatory dietary pattern
Number of subjects: 794
Study: 27304196

Group type: EXPERIMENTAL
Intervention: Vorapaxar (2.5 mg q.d. for 7 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg q.d. for 7 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vorapaxar + Aspirin (for 7 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Aspirin (for 7 days)
Number of subjects: 36
Study: 24699310

Group type: EXPERIMENTAL
Intervention: Sativex(®) low dose (5.4mg THC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sativex(®) high dose (21.6mg THC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23896849

Group type: EXPERIMENTAL
Intervention: Cognitive remediation with supplemental Internet-based homework (10 weeks of weekly group sessions and daily online cognitive exercises)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Online cognitive exercises
Number of subjects: 0
Study: 20843504

Group type: EXPERIMENTAL
Intervention: Diclectin (doxylamine succinate 10 mg-pyridoxine hydrochloride 10 mg, delayed-release preparation)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Diclectin
Number of subjects: 256
Study: 17507912

Group type: EXPERIMENTAL
Intervention: Low-nicotine cigarettes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-nicotine cigarettes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both low- and high-nicotine cigarettes
Number of subjects: 24
Study: 16914459

Group type: EXPERIMENTAL
Intervention: i.v. N-acetylcysteine (NAC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 14597936

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/d
Number of subjects: 917

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg/d
Number of subjects: 917
Study: 11109407

Group type: EXPERIMENTAL
Intervention: Video-based intervention
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study: 8737752

Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg and 6 mg
Number of subjects: 86
Study: 1331494

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g kg‐1 body mass)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control and placebo conditions
Number of subjects: 4
Study: 3874640

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 0
Study: 31559948

Group type: EXPERIMENTAL
Intervention: Alternating Pressure Mattress (APM)
Number of subjects: 2029

Group type: COMPARATOR
Intervention: High-Specification Foam Mattress (HSFM)
Number of subjects: 2029
Study: 28489759

Group type: EXPERIMENTAL
Intervention: Shen-Cao granules
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no Shen-Cao granules)
Number of subjects: 200
Study: 26042031

Group type: EXPERIMENTAL
Intervention: Acoustically controlled auditory training (ACAT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo training (Active Control Group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No intervention (Passive Control Group)
Number of subjects: 16
Study: 23680589

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) iron (Iron Sucrose 200 mg, once a week for 5 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral (p.o.) iron (ferrous sulfate 200 mg TID for 8 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21642644

Group type: EXPERIMENTAL
Intervention: Phenylephrine (100-200 µg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ephedrine (5-20 mg)
Number of subjects: 29
Study: 19451440

Group type: EXPERIMENTAL
Intervention: Baseline EORTC QLQ‐C30 physical functioning (PF) score
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Change in HRQOL dimensions, specifically PF change
Number of subjects: 540

Group type: COMPARATOR
Intervention: No other HRQOL variable
Number of subjects: 540
Study: 16719616

Group type: EXPERIMENTAL
Intervention: Applied tension technique (treatment condition)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Applied tension technique (placebo condition)
Number of subjects: 467

Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 467

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 467
Study: 15560813

Group type: EXPERIMENTAL
Intervention: Experimental anti‐plaque paste (test)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Experimental paste (minus active or negative control)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Proprietary anti‐plaque toothpaste product (positive control)
Number of subjects: 22
Study: 11736621

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (group exercise 3 times a week for 8 weeks, including calisthenics, stationary bicycling, and walking)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 10
Study: 9209247

Group type: EXPERIMENTAL
Intervention: Oral cotinine treatment (0.25 mg/kg twice a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-dose cotinine-d4 infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cotinine derived from nicotine
Number of subjects: 12
Study: 8080160

Group type: EXPERIMENTAL
Intervention: Amino acid solution containing acetate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amino acid solution without acetate
Number of subjects: 30
Study: 3454320

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29321067

Group type: EXPERIMENTAL
Intervention: MOH plus Alcohol-Containing essential oil Mouthrinse (ACM)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: MOH plus Alcohol-Free essential oil Mouthrinse (AFM)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Mechanical Oral Hygiene (MOH) only
Number of subjects: 370
Study: 27710817

Group type: EXPERIMENTAL
Intervention: Structured newborn care education programme (one-on-one educational sessions lasting 10-15 minutes each and one postpartum follow-up telephone support within two weeks after discharge)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Regular general newborn care education (control group)
Number of subjects: 143
Study: 24188861

Group type: EXPERIMENTAL
Intervention: Helping Alliance Questionnaire I (measured twice, middle and late during treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hamilton Depression Rating Scale
Number of subjects: 0
Study: 22705035

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (STPP)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Solution-focused therapy (SFT)
Number of subjects: 198
Study: 20530276

Group type: EXPERIMENTAL
Intervention: ixabepilone (40 mg/m² intravenously on day 1) plus capecitabine (2,000 mg/m² orally on days 1 through 14)
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: ixabepilone plus capecitabine
Number of subjects: 1221

Group type: COMPARATOR
Intervention: capecitabine alone (2,500 mg/m² on the same schedule)
Number of subjects: 1221
Study: 18405814

Group type: EXPERIMENTAL
Intervention: Herbst appliance (combined with fixed appliances)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Headgear (combined with fixed appliances)
Number of subjects: 48
Study: 16633890

Group type: EXPERIMENTAL
Intervention: Budesonide (Dosage Form A, 3 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Budesonide (Dosage Form A, 9 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Budesonide (Dosage Form B, 9 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12728189

Group type: EXPERIMENTAL
Intervention: Anticipatory guidance provided by pediatricians regarding contraception
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Least effective contraceptive methods
Number of subjects: 0
Study: 10663279

Group type: EXPERIMENTAL
Intervention: Ranitidine alone (150 mg preoperatively per os and 50 mg intravenously postoperatively)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ranitidine combined with dobutamine (150 mg preoperatively per os and 50 mg intravenously postoperatively + dobutamine 4 micro g. kg(‐1). min(‐1) for 3 h postoperatively)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dobutamine alone (4 micro g. kg(‐1). min(‐1) for 3 h postoperatively)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Neither ranitidine nor dobutamine (control group)
Number of subjects: 64
Study: 8797464

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (1 g/kg body weight/day for 2 days, total dose 2.0 g/kg body weight)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (0.3% albumin equivalent volume)
Number of subjects: 9
Study: 1545091

Group type: EXPERIMENTAL
Intervention: Peak expiratory flow rate measurements
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4 PM FEV1 values
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4 AM FEV1 values
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4 PM PC20 (provocative concentration of methacholine)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4 AM PC20 (provocative concentration of methacholine)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bronchial responsiveness
Number of subjects: 10
Study: 7106950

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (4% by weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Calcium supplementation (0.5% by weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low calcium diet (0.25% by weight)
Number of subjects: 12
Study: 30905652

Group type: EXPERIMENTAL
Intervention: Long-term high-dose albumin (1.5 g/kg every week)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Long-term low-dose albumin (1 g/kg body weight every 2 weeks)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Short-term albumin plus antibiotics (1.5 g/kg on day 1 and 1 g/kg on day 3)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Antibiotics alone (control group)
Number of subjects: 96
Study: 30572835

Group type: EXPERIMENTAL
Intervention: Dual-task exercise program
Number of subjects: 300

Group type: COMPARATOR
Intervention: Recruitment strategies (various approaches including information packs, presentations, testing)
Number of subjects: 300
Study: 26676176

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 53
Study: 25014045

Group type: EXPERIMENTAL
Intervention: Arm weight support device
Number of subjects: 28

Group type: COMPARATOR
Intervention: Traditional physiotherapy
Number of subjects: 28
Study: 18267994

Group type: EXPERIMENTAL
Intervention: Multidisciplinary patient education intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90
Study: 15209626

Group type: EXPERIMENTAL
Intervention: Combination therapy (IFN-alpha-2b + hepatitis B vaccine)
Number of subjects: 50

Group type: COMPARATOR
Intervention: IFN-alpha-2b monotherapy
Number of subjects: 50
Study: 11324727

Group type: EXPERIMENTAL
Intervention: Twice-daily 3 MU of IFN beta (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Once-daily 6 MU of IFN-beta (group B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adverse effects of IFN
Number of subjects: 20
Study: 9040326

Group type: EXPERIMENTAL
Intervention: Routine clinic review
Number of subjects: 210

Group type: COMPARATOR
Intervention: Routine physical examination
Number of subjects: 210
Study: 7943596

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 0
Study: 3285170

Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mg. kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 11427138

Group type: EXPERIMENTAL
Intervention: Condom use during more than 25% of sex acts
Number of subjects: 528

Group type: COMPARATOR
Intervention: Initial 150-day interval
Number of subjects: 528

Group type: COMPARATOR
Intervention: Final 150-day interval
Number of subjects: 528
Study: 30690691

Group type: EXPERIMENTAL
Intervention: VEL-091604 cream applied 2 times daily for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1% hydrocortisone acetate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: VEL-091604 cream in atopic dermatitis subjects
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28592196

Group type: EXPERIMENTAL
Intervention: Forever Free (FF) relapse prevention booklets
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control booklet (Surgeon General's report, SG)
Number of subjects: 225
Study: 26462570

Group type: EXPERIMENTAL
Intervention: Short-term meditation (MG) with positive suggestions
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Short-term meditation (MG) with negative suggestions
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Expectation control group (ECG) with positive suggestions
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Expectation control group (ECG) with negative suggestions
Number of subjects: 59

Group type: COMPARATOR
Intervention: Passive control group (CG)
Number of subjects: 59
Study: 25416602

Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate (OCA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Surgical repair
Number of subjects: 42
Study: 22592214

Group type: EXPERIMENTAL
Intervention: Midazolam (0.05mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline solution (0.9% NaCl)
Number of subjects: 100
Study: 19878508

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg weekly for 4 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 17367313

Group type: EXPERIMENTAL
Intervention: 500 microg alum-formulated rhGAD65
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 20 microg alum-formulated rhGAD65
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 15922068

Group type: EXPERIMENTAL
Intervention: 10% coherence level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30% coherence level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50% coherence level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100% coherence level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target-alone condition
Number of subjects: 0
Study: 11828040

Group type: EXPERIMENTAL
Intervention: Bronchial hyperresponsiveness (BHR) tests
Number of subjects: 1633

Group type: EXPERIMENTAL
Intervention: Symptom history
Number of subjects: 1633

Group type: EXPERIMENTAL
Intervention: Logistic regression model with four symptoms
Number of subjects: 1633

Group type: EXPERIMENTAL
Intervention: Logistic regression model with symptoms, free running test, and methacholine inhalation challenge results
Number of subjects: 1633
Study: 10036612

Group type: EXPERIMENTAL
Intervention: Haloperidol 1.0 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Haloperidol 2.0 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8751336

Group type: EXPERIMENTAL
Intervention: Visaline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1975113

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg/kg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 99
Study: 6944708

Group type: EXPERIMENTAL
Intervention: Reserpine 0.5 mg i.m.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Haloperidol 0.5 mg i.m.
Number of subjects: 8
Study: 31713262

Group type: EXPERIMENTAL
Intervention: Basic sensory intervention (SI) including hearing and vision assessment and provision of glasses and/or hearing aids
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Extended sensory intervention (SI) with additional weekly visits from a sensory support therapist (SST)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Basic sensory intervention (SI)
Number of subjects: 19
Study: 30601215

Group type: EXPERIMENTAL
Intervention: Confident, high-power body language
Number of subjects: 200

Group type: COMPARATOR
Intervention: Unconfident, low-power body language
Number of subjects: 200
Study: 28412009

Group type: EXPERIMENTAL
Intervention: Music during ESWL
Number of subjects: 95

Group type: COMPARATOR
Intervention: No music during ESWL
Number of subjects: 95
Study: 25820213

Group type: EXPERIMENTAL
Intervention: WBV+ES
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: WBV30/ES30
Number of subjects: 13

Group type: COMPARATOR
Intervention: WBV
Number of subjects: 13

Group type: COMPARATOR
Intervention: ES
Number of subjects: 13
Study: 24375332

Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 47
Study: 22571890

Group type: EXPERIMENTAL
Intervention: Watchful Waiting Death (WWD)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Perioperative Death (PD)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Successful Operation (SO)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group (statistical treatment guidelines for AAA)
Number of subjects: 208
Study: 19683469

Group type: EXPERIMENTAL
Intervention: Combined oVEMP and cVEMP test
Number of subjects: 32

Group type: COMPARATOR
Intervention: Individual oVEMP and cVEMP tests
Number of subjects: 32
Study: 17559755

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Duloxetine (60 mg)
Number of subjects: 294
Study: 15212720

Group type: EXPERIMENTAL
Intervention: VLTS-589 (plasmid-expressing Del-1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12418673

Group type: EXPERIMENTAL
Intervention: Lyophilized PRP-T with DTP
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Liquid DTP/PRP-T formulation
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Liquid DTP/PRP-T formulation (Part 2)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Booster dose of PRP-T/DTP
Number of subjects: 284

Group type: COMPARATOR
Intervention: DTP alone
Number of subjects: 284
Study: 9848776

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/d)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8090847

Group type: EXPERIMENTAL
Intervention: Research report with an example included (group 1)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Research report without an example (group 2)
Number of subjects: 69
Study: 2589059

Group type: EXPERIMENTAL
Intervention: Intraocular lenses with ultraviolet absorbing chromophore
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard posterior chamber intraocular lens
Number of subjects: 55
Study: 31855498

Group type: EXPERIMENTAL
Intervention: Antioxidant supplements (vitamins A, C, and E; carotenoids; coenzyme Q10) before and during treatment
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Vitamin B12 use before and during chemotherapy
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Iron use during chemotherapy
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Multivitamin use
Number of subjects: 1134
Study: 31058727

Group type: COMPARATOR
Intervention: Classical group (n=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Piezo group (n=15)
Number of subjects: 30
Study: 28416405

Group type: EXPERIMENTAL
Intervention: SLEEP Inventory (Sex, Left heart failure, ESS, Enlarged neck, weight [in Pounds], Insulin resistance/diabetes, and National Institutes of Health Stroke Scale)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Berlin Questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Snoring, Tiredness, Observed apnea, high blood Pressure, Body mass index, Age, Neck circumference, and Gender instrument
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sleep Apnea Clinical Score
Number of subjects: 0
Study: 26162815

Group type: EXPERIMENTAL
Intervention: Inpatient cardiac rehabilitation (Group 1)
Number of subjects: 834

Group type: COMPARATOR
Intervention: No inpatient cardiac rehabilitation (Group 2)
Number of subjects: 834
Study: 23381494

Group type: EXPERIMENTAL
Intervention: Intranasal mometasone furoate (MF) for 6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intranasal mometasone furoate (MF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 21554040

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19356485

Group type: COMPARATOR
Intervention: Normal geometry
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Concentric remodeling
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Eccentric hypertrophy
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Concentric hypertrophy
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Baseline LVMi increase
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Baseline RWT increase
Number of subjects: 603